Serial circulating tumor DNA analysis can demonstrate rapid clonal dynamics that evolve during response and resistance to both standard chemotherapy and targeted therapy of BRAF-mutant colon cancer ...

A groundbreaking study is providing new hope for patients with advanced or metastatic colon cancer, particularly those with something known as a BRAF V600E mutation, a historically difficult-to-treat ...

Traditional FDA approval covers encorafenib plus cetuximab with fluorouracil-based chemotherapy for adult metastatic CRC with BRAF V600E mutations confirmed by an FDA-authorized test. BREAKWATER ...

Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Braftovi plus Erbitux and FOLFIRI showed significant ORR benefits in BRAF V600E–mutant mCRC compared to the control regimen. The combination therapy achieved a confirmed ORR of 64.4% versus 39.2% with ...

Full approval was driven by BREAKWATER Phase III outcomes, including PFS HR 0.53 and OS HR 0.49 versus fluoropyrimidine/oxaliplatin-based chemotherapy options ± ...

Pfizer (NYSE:PFE) and Astellas reported Phase 3 data showing PADCEV plus Keytruda delivered significant clinical benefits in muscle-invasive bladder cancer. The combination was associated with ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Clinical Utility of Molecular Tumor Board Review for Identification of Possible Germline Pathogenic Variants on Tumor Next-Generation Sequencing Reports We demonstrate dynamic evolution of resistance ...

Phase III trial results supported recent FDA approval for patients with BRAF V600E mutations Data from this multi-institutional collaboration across 28 countries supported the accelerated approval of ...